EIK1003, a PARP1-selective inhibitor, in combination with paclitaxel (PTX): Initial combination and updated monotherapy results from a Phase 1/2 study EIK1003-001 in advanced solid tumors – Poster Presentation, ASCO 2026
Saturday, May 30, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: The article discusses the initial combination and updated monotherapy results of EIK1003, a PARP1-selective inhibitor, in a Phase 1/2 study (EIK1003-001) for advanced solid tumors. The findings were presented at ASCO 2026, highlighting the potential effectiveness of EIK1003 when used alongside paclitaxel. This research could pave the way for new treatment options in oncology.
Price reaction · baseline $10.84 (2026-05-29 close) · 5 other EIKN headline(s) in the window, move may be shared
day 0 close · peak
-0.5%
Market Sentiment Analysis
POSITIVE FACTORS
EIK1003 shows promise as a PARP1-selective inhibitor.
Combination with paclitaxel may enhance treatment efficacy.
Initial results indicate potential for advanced solid tumors.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~24 mo
Minimal dilution risk
Lead asset
EIK1001
Phase 2 · NSCLC
Full Press Release Details
05/30/2026
EIK1003, a PARP1-selective inhibitor, in combination with paclitaxel (PTX): Initial combination and updated monotherapy results from a Phase 1/2 study EIK1003-001 in advanced solid tumors – Poster Presentation, ASCO 2026
Share
Share on LinkedIn
Frequently Asked Questions
What is EIK1003?
EIK1003 is a PARP1-selective inhibitor being studied for advanced solid tumors.
What were the results of the Phase 1/2 study?
The study presented initial combination and updated monotherapy results for EIK1003.
Where were the results presented?
The results were presented at ASCO 2026.
What is the combination therapy with EIK1003?
EIK1003 is being tested in combination with paclitaxel (PTX).